Dyne Therapeutics, Inc. Facility Costs
Dyne Therapeutics, Inc. (DYN) reported Facility Costs of $12.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FacilityCosts · last filed 2026-07-29
- Dyne Therapeutics, Inc. facility costs for the quarter ending 2026-06-30 was $12.50M, a 68.51% increase year-over-year.
- Dyne Therapeutics, Inc. facility costs for the quarter ending 2026-03-31 was $11.86M, a 71.49% increase year-over-year.
- Dyne Therapeutics, Inc. facility costs for the quarter ending 2025-12-31 was $2.75M, a 51.43% decline year-over-year.
- Dyne Therapeutics, Inc. facility costs for the quarter ending 2025-09-30 was $9.45M, a 57.78% increase year-over-year.
- Dyne Therapeutics, Inc. facility costs for fiscal 2025 was $29.45M, a 28.04% increase from fiscal 2024.
- Dyne Therapeutics, Inc. facility costs for fiscal 2024 was $23.00M, a 12.65% increase from fiscal 2023.
- Dyne Therapeutics, Inc. facility costs for fiscal 2023 was $20.42M, a 5.81% increase from fiscal 2022.
- Dyne Therapeutics, Inc. facility costs for fiscal 2022 was $19.30M.
| Period end | Facility Costs 3 month | Facility Costs 6 month | Facility Costs 9 month | Facility Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.50M 10-Q · filed 2026-07-29 | $24.38M 10-Q · filed 2026-07-29 | $27.11M derived: sum of 3 quarters · filed 2026-07-29 | $36.55M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $11.86M 10-Q · filed 2026-05-11 | $14.61M derived: sum of 2 quarters · filed 2026-05-11 | $24.05M derived: sum of 3 quarters · filed 2026-05-11 | $31.47M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.20M derived: sum of 2 quarters · filed 2026-03-02 | $19.61M derived: sum of 3 quarters · filed 2026-07-29 | $29.45M 10-K · filed 2026-03-02 |
| 2025-09-30 | $9.45M 10-Q · filed 2025-11-05 | $16.87M derived: sum of 2 quarters · filed 2026-07-29 | $26.70M 10-Q · filed 2025-11-05 | $29.44M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $7.42M 10-Q · filed 2026-07-29 | $14.33M 10-Q · filed 2026-07-29 | $19.99M derived: sum of 3 quarters · filed 2026-07-29 | $25.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $6.92M 10-Q · filed 2026-05-11 | $12.57M derived: sum of 2 quarters · filed 2026-05-11 | $18.56M derived: sum of 3 quarters · filed 2026-05-11 | $24.18M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.64M derived: sum of 2 quarters · filed 2026-03-02 | $17.26M derived: sum of 3 quarters · filed 2026-03-02 | $23.00M 10-K · filed 2026-03-02 |
| 2024-09-30 | $5.99M 10-Q · filed 2025-11-05 | $11.60M derived: sum of 2 quarters · filed 2025-11-05 | $17.34M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $5.62M 10-Q · filed 2025-07-28 | $10.51M 10-Q · filed 2025-07-28 | ||
| 2024-03-31 | $4.89M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $20.42M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $19.30M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |